Use of a buprenorphine-based pain management protocol is associated with reduced opioid requirements and pain on swallowing in oral mucositis: a retrospective cohort study.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 12 10 2021
accepted: 25 03 2022
pubmed: 12 4 2022
medline: 31 5 2022
entrez: 11 4 2022
Statut: ppublish

Résumé

The aim of this study is to ascertain the analgesic efficacy and total oral morphine equivalent daily dose (OMEDD) effect of a buprenorphine-based analgesic protocol in the treatment of severe Oral Mucositis (OM). This is a retrospective cohort study. This study was done in a single Quaternary Referral Centre, Haematology Unit. Fifty-four stem cell transplant patients suffering at least grade 3 oral mucositis (OM), 24 prior to [Pr-I] and 30 subsequent to [Po-I] a buprenorphine-based OM analgesic protocol. We analysed data from the above subjects with the primary outcome measure of difference in total OMEDDs from all opioid types and administration routes, and secondary outcome measures of area under the curve (AUC) of 11-point Numerical Rating Scale (NRS-11) pain assessments, sedation scores and respiratory rate. Post-protocol patients' total OMEDD requirements were significantly reduced [Pr-I: 1961 (1365)mg; Po-I: 928 (625)mg, p = 0.02], as were total NRS-11:hours AUC on swallowing [Pr-I: 54(24) score-hours; Po-I: 41(18) score-hours, p < 0.001]. There were no significant differences in objective measures of OM severity between groups (Number of Grade 3 or 4 OM severity assessments [mean (SD)] Pr-I: 5 (6.2); Po-I: 7 (5.1) or number of days Neutrophil count 0.0 or 0.1 × 10 Use of Buprenorphine via transdermal, sublingual and intravenous Patient Controlled Analgesia (PCA) delivery as part of an analgesic protocol for severe post stem cell transplant oral mucositis in adult patients appears to significantly reduce opioid requirements and pain on swallowing. Further randomised prospective work is required to confirm these associations.

Identifiants

pubmed: 35403901
doi: 10.1007/s00520-022-07014-5
pii: 10.1007/s00520-022-07014-5
doi:

Substances chimiques

Analgesics, Opioid 0
Buprenorphine 40D3SCR4GZ
Morphine 76I7G6D29C

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6013-6020

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Saunders DP, Epstein JB, Elad S et al (2013) Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support. Care Cancer Off. J Multinatl Assoc Support Care Cancer 21:3191–207
doi: 10.1007/s00520-013-1871-y
Angst MS (2015) Intraoperative Use of Remifentanil for TIVA: Postoperative pain, acute tolerance, and opioid-induced hyperalgesia. J Cardiothorac Vasc Anesth Elsevier 29:S16-22
doi: 10.1053/j.jvca.2015.01.026
Simonnet G, Rivat C (2003) Opioid-induced hyperalgesia: abnormal or normal pain? NeuroReport 14:1–7
doi: 10.1097/00001756-200301200-00001
Schaefer CP, Tome ME, Davis TP (2017) The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse. Fluids Barriers CNS 14:32
doi: 10.1186/s12987-017-0080-3
Ooi K: Faculty of Pain Medicine | ANZCA: Official Opioid Dose Equivalence. [Internet]FPMANZCA Prof. Doc. [Internet]2019 [cited 2021]Retrieved from: http://www.anzca.edu.au/documents/anzcafpm-good-prescribing-practice-20150814.pdf
Nielsen S, National Drug and Alcohol Research Centre (Australia): Comparing opioids: a guide to estimating oral morphine equivalents (OME) in research. 2014,
Voorhis C, Morgan B: Understanding power and rules of thumb for determining sample size. Tutor. Quant. Methods Psychol. 32007
Hussain AM, Khan FA, Ahmed A et al (2013) Effect of gender on pain perception and analgesic consumption in laparoscopic cholecystectomy: An observational study. J Anaesthesiol Clin Pharmacol 29:337–341
doi: 10.4103/0970-9185.117095
Aubrun F, Salvi N, Coriat P et al (2005) Sex- and age-related differences in morphine requirements for postoperative pain relief. Anesthesiology 103:156–160
doi: 10.1097/00000542-200507000-00023
Coda BA, O’Sullivan B, Donaldson G et al (1997) Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation. Pain 72:333–346
doi: 10.1016/S0304-3959(97)00059-6
Roy SD, Flynn GL (1988) Solubility and Related Physicochemical Properties of Narcotic Analgesics. Pharm Res 5:580–586
doi: 10.1023/A:1015994030251
Vokurka S, Skardova J, Karas M et al (2010) Oropharyngeal mucositis pain treatment with transdermal buprenorphine in patients after allogeneic stem cell transplantation. J Pain Symptom Manage 39:e4-6
doi: 10.1016/j.jpainsymman.2010.02.003
Kress HG (2009) Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain Lond Engl 13:219–230
doi: 10.1016/j.ejpain.2008.04.011
James PJ, Howard RF, Williams DG (2010) The addition of ketamine to a morphine nurse- or patient-controlled analgesia infusion (PCA/NCA) increases analgesic efficacy in children with mucositis pain. Paediatr Anaesth 20:805–811
doi: 10.1111/j.1460-9592.2010.03358.x
White MC, Hommers C, Parry S et al (2011) Pain management in 100 episodes of severe mucositis in children. Paediatr Anaesth 21:411–416
doi: 10.1111/j.1460-9592.2010.03515.x
Prakash S, Meena JP, Gupta AK et al (2020) Ketamine mouthwash versus placebo in the treatment of severe oral mucositis pain in children with cancer: A randomized double-blind placebo-controlled trial. Pediatr Blood Cancer 67:e28573
doi: 10.1002/pbc.28573
Shillingburg A, Kanate AS, Hamadani M et al (2017) Treatment of severe mucositis pain with oral ketamine mouthwash. Support. Care Cancer Off. J Multinatl Assoc Support Care Cancer 25:2215–9
doi: 10.1007/s00520-017-3627-6
Ryan AJ, Lin F, Atayee RS (2009) Ketamine mouthwash for mucositis pain. J. Palliat. Med Mary Ann Liebert Inc publishers 12:989–91
Lin Y-C, Sentivany-Collins S: The analgesic response to intravenous lidocaine in the treatment of mucositis pain in children. [Internet]Abstr. - Anesthesiol. Annu. Meet. [Internet] American Society of Anesthesiologists[cited 2022]Retrieved from: http://www.asaabstracts.com/strands/asaabstracts/abstract.htm?year=2000&index=15&absnum=1228
Bensinger W, Schubert M, Ang K-K et al (2008) NCCN Task Force Report: Prevention and Management of Mucositis in Cancer Care. J Natl Compr Canc Netw 6:S-1-S-21
doi: 10.6004/jnccn.2008.2001
Demarosi F, Lodi G, Soligo D et al (2004) Transdermal fentanyl in HSCT patients: an open trial using transdermal fentanyl for the treatment of oral mucositis pain. Bone Marrow Transplant 33:1247–1251
doi: 10.1038/sj.bmt.1704515
Schug SA, Palmer GM, Scott DA et al (2016) Acute pain management: scientific evidence, fourth edition, 2015. Med J Aust 204:315–7
doi: 10.5694/mja16.00133
Kishimoto M, Akashi M, Tsuji K et al (2017) Intensity and duration of neutropenia relates to the development of oral mucositis but not odontogenic infection during chemotherapy for hematological malignancy. PLOS ONE Public Library of Science 12:e0182021
doi: 10.1371/journal.pone.0182021

Auteurs

Ilonka Meyer (I)

Department of Anesthesia & Inpatient Pain Services, Austin Hospital, Level 2 Austin Towers, 145 Studley Rd Heidelberg, Melbourne, VIC, 3084, Australia.

Brandon Chan (B)

Department of Anesthesia & Inpatient Pain Services, Austin Hospital, Level 2 Austin Towers, 145 Studley Rd Heidelberg, Melbourne, VIC, 3084, Australia.

Emma Cohen (E)

Department of Haematology, Austin Hospital, 145 Studley Rd Heidelberg, Melbourne, VIC, 3084, Australia.

Esther Dube (E)

Department of Inpatient Pain Services, Austin Hospital, Level 2 Austin Towers, 145 Studley Rd, HeidelbergMelbourne, VIC, 3084, Australia.

Raymond Hu (R)

Department of Anesthesia & Inpatient Pain Services, Austin Hospital, Level 2 Austin Towers, 145 Studley Rd Heidelberg, Melbourne, VIC, 3084, Australia.

Megan Yeomans (M)

Department of Inpatient Pain Services, Austin Hospital, Level 2 Austin Towers, 145 Studley Rd, HeidelbergMelbourne, VIC, 3084, Australia.

Frances Pontonio (F)

Department of Inpatient Pain Services, Austin Hospital, Level 2 Austin Towers, 145 Studley Rd, HeidelbergMelbourne, VIC, 3084, Australia.

Charlotte Heldreich (C)

Department of Anesthesia & Inpatient Pain Services, Austin Hospital, Level 2 Austin Towers, 145 Studley Rd Heidelberg, Melbourne, VIC, 3084, Australia.

Stiofan O'Conghaile (S)

Department of Anesthesia & Inpatient Pain Services, Austin Hospital, Level 2 Austin Towers, 145 Studley Rd Heidelberg, Melbourne, VIC, 3084, Australia.

Natasha Holmes (N)

Department of Data Analytics Research & Evaluation Centre, Austin Hospital, 145 Studley Rd Heidelberg, Melbourne, VIC, 3084, Australia.

Nada Maroon (N)

Department of Data Analytics Research & Evaluation Centre, Austin Hospital, 145 Studley Rd Heidelberg, Melbourne, VIC, 3084, Australia.

Laurence Weinberg (L)

Department of Anesthesia & Inpatient Pain Services, Austin Hospital, Level 2 Austin Towers, 145 Studley Rd Heidelberg, Melbourne, VIC, 3084, Australia.

Chong O Tan (CO)

Department of Anesthesia & Inpatient Pain Services, Austin Hospital, Level 2 Austin Towers, 145 Studley Rd Heidelberg, Melbourne, VIC, 3084, Australia. drchongtan@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH